Ashraf Farrag

Oncologist

[Ashraf Farrag @ashraffarrag]

"كل الناس يغدو فبائع نفسه فمعتقها أو موبقها"

[Ashraf Farrag @ashraffarrag]

@Mobily1100
تقدمت بطلب تركيب موبايلي فايبر وتم تحديد موعد ولم يأتي احد من الشركة في الموعد المحدد ولم اتلقى اي إفادة من التواصل مع ١١٠٠

[Tom Powles @tompowles1]

3 studies testing Perioperative immune bases therapy (EVP or Gem/Cis/Durva) in muscle invasive bladder all have shown an OS advantage vs standard of care. KN905 (EVP) is distinct in that it’s in a cisplatin ineligible population (accounting for the poor performance of the control arm). It’s also a smaller trial. The control arm of KN-B15 performed slightly better than NIAGARA (Gem/cis for both), but the trials are otherwise similar. The pCR in the EVP trails and the consistent efficacy of EVP is striking. #GU26

[David Sher @DavidSherMD]

I’ve been looking forward to this paper since the ASTRO Plenary talk in 2023.

HYPNO-RT is out: is it worth the wait?

https://t.co/RbBrDOriMo

[Martin Tom @MartinTomMD]

Treatment for Brain Metastases With Stereotactic Radiation vs Hippocampal-Avoidance Whole Brain Radiation
A Randomized Clinical Trial
https://t.co/ViQTBACbME

[Ashraf Farrag @ashraffarrag]

@blu_sia @StuffWorthSee In Rome too

[Stuff Worth Seeing @StuffWorthSee]

drink water but make it italian

[Ash Paul @pash22]

Absence of evidence is not evidence of absence
https://t.co/QjhdJIYVXx

[ACRO - American College of Radiation Oncology @ACRORadOnc]

ACRO recently collaborated on a consensus statement on standards for dose evaluation and reporting in patients with multiple courses of #radiationtherapy. The policy review is now published in @TheLancetOncol. Check it out: https://t.co/qt4IQM2pWV

[Jennifer Le Guévelou @JennKa12]

Optimizing prostate cancer stereotactic body radiotherapy: margins, dose, or target volume-de-intensification? - ScienceDirect https://t.co/q1WU9z81M7

[Radiation Medicine Program @RadMedPM]

💡New article from Radiation Therapist Vickie Kong and team looks at time toxicity in CBCT-guided radiation therapy using a retrospective analysis🔗: https://t.co/j6GwJRaJsQ

[Matt Spraker @SprakerMDPhD]

Nice paper on abdo/pelvic sarcoma in Advances from the MDACC team.

Well planned and delivered VMAT is incredibly safe, very low toxicity risk.

Also a demonstration of how high grade liposarcoma locally recurs a lot!

Don’t sleep on pre-op radiation for these folks.

[David Palma, MD, PhD @drdavidpalma]

Want to try Sim-Free RT for palliative cases?

Some recommendations here, led by @Melissa_O_Neil

⬇️⬇️⬇️

[ASTRO @ASTRO_org]

In this new #RedJournal article, IROCK Contouring Guidelines now available for Renal SABR! https://t.co/SYwZKnuku7

[Ashraf Farrag @ashraffarrag]

@NoContextBrits

[ASTRO @ASTRO_org]

In this new #RedJournal article, the authors share practical strategies for delivering SABR and LDRT in patients with widespread polymetastatic disease. Read more here: https://t.co/XWvmsQxAj2

[ASTRO @ASTRO_org]

New in the #RedJournal: replanned TROG 12.01 unilateral cases to define guidelines for unilateral RT planning with maximal midline and contralateral sparing. @TROGfightcancer #RadOnc #HNcsm https://t.co/yvE7RTRk3A

[Yakup Ergün @dr_yakupergun]

#ESMO25 Top Breast Cancer Trials and Key Results👇

[George Pentheroudakis @GPentheroudakis]

My personal favourite from ESMO25, looking forward to survival outcomes…

[Pablo Mando @PabloMando]

HER eBC management is improving survival but more complex. Here is a proposed algorithm with new advances post @myESMO #ESMO25 What do you think? What would you change? @matteolambe @PTarantinoMD @E_de_Azambuja @stolaney1 @Rodrosb @ElisaAgostinett @ErikaHamilton9 @hoperugo